Abstract
In 2001 the Italian Government defined Essential Assistance Levels (LEA), which can be considered as an important step forward in the health care system. The Italian health care system would provide payment of essential and uniform aid services in order to safeguard many values such as human dignity, personal health, equal assistance and good health practices. The Ministry of Health has worked to rationalize the National Formulary and to define evaluation methods for drugs in order to choose what to reimburse without penalizing the rights of the individual and society.
This paper describes how this job of rationalization was done and tries to illustrate the choices made in Italy by the use of two meaningful examples (statins and rivastigmine).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atella, V. (2000) Drug Cost Containment Policies in Italy: Are They Really Effective in the Long-Run? The Case of Minimum Reference Price. Health Policy 50, 197-218.
Begaud, B., Bergman, U., Eichler, H. G., Leufkens, H. G., and Meier, P. J. (2000) Drug Reimbursement: Indicators of Inappropriate Resource Allocation. British Journal of Clinical Pharmacology 54, 528-534.
Braga, M., and Cislaghi, C. (2000) The Evaluation of Efficacy and Efficiency in the Health Care Sector: Separate or Integrated Moments? Annali di Igiene 14, 409-418.
Fattore, G., and Jommi, C. (2000) The New Pharmaceutical Policy in Italy. Health Policy 46, 21-41.
Pavenik, N. (2000) Do Pharmaceutical Price Respond to Potential Patient Out-of-Pocket Expenses? RAND Journal of ECONOMICS 33, 469-487.
Rice, N., and Smith, P. C. (2000) Capitation and Risk Adjustment in Health Care. Health Care Management Science 3, 73-75.
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., and Braunwald, E. (2000) The Effect of Pravastatin on Coronary Events After Myocardical Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators. New England Journal of Medicine 335, 1001-1009.
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., and Packard, C. J., The West of Scotland Coronary Prevention Study Group. (2000) Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. New England Journal of Medicine 333, 1301-1307.
The Long Term Interventions With Pravastatin in Ischemic Disease (LIPID) Study Group. (2000) Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine 339, 1349.
The Scandinavian Simvastatin Survival Study Group. (2000) Randomised Trial of Cholesterol Lowering in 4.444 Patients With Coronary Heart Disease. The Scandinavian Simvastatin Survival Study. Lancet 344, 1383.
Trabucchi, M. (2000) An Economic Perspective on Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology 12, 29-38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernardi, A., Pegoraro, R. Italian Drug Policy: Ethical Aims of Essential Assistance Levels. Health Care Analysis 11, 279–286 (2003). https://doi.org/10.1023/B:HCAN.0000010056.05684.22
Issue Date:
DOI: https://doi.org/10.1023/B:HCAN.0000010056.05684.22